Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > LATEST
LATEST
-
REGULATORY Health Minister Avoids Speculation on Impact of US Drug Price Cuts
September 16, 2025
-
BUSINESS AbbVie Japan Seeks Rinvoq Label Expansion for Polyarticular JIA
September 16, 2025
-
BUSINESS Clenafin Authorized Generic Hits Japan Market: Kaken
September 16, 2025
-
BUSINESS Lilly Confirms Safety of Oral GLP-1 Orforglipron in Japan PIII
September 16, 2025
-
BUSINESS Pfizer’s Ulcerative Colitis Drug Velsipity Now Available in Japan
September 16, 2025
-
BUSINESS Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
-
REGULATORY Tensions Flare at Chuikyo over Premiums for Generic Dispensing
September 16, 2025
-
ORGANIZATION JPMA Names Ex-MHLW Pharma Official Yoshida as Senior Managing Director
September 12, 2025
-
BUSINESS Eisai Sees “Best-in-Class” Promise for E2086 as Once-Daily Narcolepsy Drug
September 12, 2025
-
BUSINESS LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
-
BUSINESS Enhertu’s Tumor-Agnostic Use Now under EU Review: Daiichi Sankyo
September 12, 2025
-
BUSINESS Sawai, Nichi-Iko to Consolidate 15 APIs as Sector Tackles Small-Lot Production
September 11, 2025
-
ORGANIZATION JPMA Plans Joint Training with HCPs to Improve Promo Materials: Review Board Chair
September 11, 2025
-
BUSINESS Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
-
BUSINESS Welireg Expected to Preserve Organ Function in VHL Disease: Urologist
September 11, 2025
-
REGULATORY Motegi Calls for Lowering Generic Prices by Consolidation: LDP Race
September 11, 2025
-
REGULATORY Lawmakers Urge Chuikyo to Respect Public-Private Council Views
September 11, 2025
-
REGULATORY MHLW Panel Urges Tighter Scrutiny of GLP-1 “Weight Loss” Ads
September 11, 2025
-
REGULATORY JPMA Pushes for Mandatory Collection of Medical Data, JMA Fires Back
September 11, 2025
-
REGULATORY Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…